Connect Biopharma Holdings Ltd
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CONNECT BIOPHARMA HOLDINGS LIMITED | |||
| DATE: March 31, 2025 | BY: | /s/ BARRY D. QUART | |
|---|---|---|---|
| Barry D. Quart, Pharm.D.Chief Executive Officer | |||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Barry D. Quart as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, with respect to this annual report and any and all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all the said attorney-in-fact and agent or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ BARRY D. QUART | Chief Executive Officer and Director | March 31, 2025 |
| Barry D. Quart, Pharm.D. | (Principal Executive Officer) | |
| /s/ LISA PERAZA | Vice President, Finance | March 31, 2025 |
| Lisa Peraza, CPA | (Principal Financial and Accounting Officer) | |
| /s/ KLEANTHIS G. XANTHOPOULOS | Chairman of the Board of Directors | March 31, 2025 |
| Kleanthis G. Xanthopoulos, Ph.D. | ||
| /s/ KAN CHEN | Director | March 31, 2025 |
| Kan Chen, Ph.D. | ||
| /s/ JAMES Z. HUANG | Director | March 31, 2025 |
| James Z. Huang, MBA | ||
| /s/ JEAN LIU | Director | March 31, 2025 |
| Jean Liu, J.D. | ||
| /s/ KAREN J. WILSON | Director | March 31, 2025 |
| Karen J. Wilson, CPA | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.